Rangasamy, LoganathanRamos González, Ana MaríaDi Geronimo Quintero, BrunoCoderch Boué, ClairePascual-Teresa Fernández, Beatriz deZapico Rodríguez, José MaríaOrtín Remón, Irene2022-02-152022-02-152019-02-15http://hdl.handle.net/10637/13382Molecules, e-ISSN 1420-3049 2019, 24, 2982Matrix metalloproteinases (MMPs) are a family of zinc- and calcium-dependent endopeptidases which are secreted or anchored in the cell membrane and are capable of degrading the multiple components of the extracellular matrix (ECM). MMPs are frequently overexpressed or highly activated in numerous human diseases. Owing to the important role of MMPs in human diseases, many MMP inhibitors (MMPIs) have been developed as novel therapeutics, and some of them have entered clinical trials. However, so far, only one MMPI (doxycycline) has been approved by the FDA. Therefore, the evaluation of the activity of a specific subset of MMPs in human diseases using clinically relevant imaging techniques would be a powerful tool for the early diagnosis and assessment of the efficacy of therapy. In recent years, numerous MMPIs labeled imaging agents have emerged. This article begins by providing an overview of the MMP subfamily and its structure and function. The latest advances in the design of subtype selective MMPIs and their biological evaluation are then summarized. Subsequently, the potential use of MMPI-labeled diagnostic agents in clinical imaging techniques are discussed, including positron emission tomography (PET), single-photon emission computed tomography (SPECT) and optical imaging (OI). Finally, this article concludes with future perspectives and clinical utility.application/pdfenopen accessMatrix metalloproteinases (MMPs)Positron emission tomography (PET)Single-photon emission computed tomography (SPECT)Optical imaging (OI)Artículohttps:// doi:10.3390/molecules24162982https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es